Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

E Van Cutsem, P M Hoff, P Harper, R M Bukowski, D Cunningham, P Dufour, U Graeven, J Lokich, S Madajewicz, J A Maroun, J L Marshall, E P Mitchell, G Perez-Manga, P Rougier, W Schmiegel, J Schoelmerich, A Sobrero, R L Schilsky, E Van Cutsem, P M Hoff, P Harper, R M Bukowski, D Cunningham, P Dufour, U Graeven, J Lokich, S Madajewicz, J A Maroun, J L Marshall, E P Mitchell, G Perez-Manga, P Rougier, W Schmiegel, J Schoelmerich, A Sobrero, R L Schilsky

Abstract

This study evaluates the efficacy of capecitabine using data from a large, well-characterised population of patients with metastatic colorectal cancer (mCRC) treated in two identically designed phase III studies. A total of 1207 patients with previously untreated mCRC were randomised to either oral capecitabine (1250 mg m(-2) twice daily, days 1-14 every 21 days; n=603) or intravenous (i.v.) bolus 5-fluorouracil/leucovorin (5-FU/LV; Mayo Clinic regimen; n=604). Capecitabine demonstrated a statistically significant superior response rate compared with 5-FU/LV (26 vs 17%; P<0.0002). Subgroup analysis demonstrated that capecitabine consistently resulted in superior response rates (P<0.05), even in patient subgroups with poor prognostic indicators. The median time to response and duration of response were similar and time to progression (TTP) was equivalent in the two arms (hazard ratio (HR) 0.997, 95% confidence interval (CI) 0.885-1.123, P=0.95; median 4.6 vs 4.7 months with capecitabine and 5-FU/LV, respectively). Multivariate Cox regression analysis identified younger age, liver metastases, multiple metastases and poor Karnofsky Performance Status as independent prognostic indicators for poor TTP. Overall survival was equivalent in the two arms (HR 0.95, 95% CI 0.84-1.06, P=0.48; median 12.9 vs 12.8 months, respectively). Capecitabine results in superior response rate, equivalent TTP and overall survival, an improved safety profile and improved convenience compared with i.v. 5-FU/LV as first-line treatment for MCRC. For patients in whom fluoropyrimidine monotherapy is indicated, capecitabine should be strongly considered. Following encouraging results from phase I and II trials, randomised trials are evaluating capecitabine in combination with irinotecan, oxaliplatin and radiotherapy. Capecitabine is a suitable replacement for i.v. 5-FU as the backbone of colorectal cancer therapy.

Figures

Figure 1
Figure 1
Response rates by subpopulation.
Figure 2
Figure 2
Time to disease progression.
Figure 3
Figure 3
Overall survival: updated June 2002.

References

    1. André T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F, Beerblock K, Bouche O, Carola E, Merrouche Y, Morvan F, Dupont-Andre G, de Gramont A (1999) Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17: 3560–3568
    1. Borner M, Dietrich D, Popescu R, Wernli M, Roth AD, Saletti P, Rauch DP, Herrmann R, Koberle D, Pestalozzi B, Honegger H, Castiglione-Gertsch M, Goldhirsch A (2003) A randomized phase II trial of capecitabine (CAP) and two different schedules of irinotecan (IRI) in first-line treatment of metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 22: 266 (Abstract 1068)
    1. Borner M, Schöffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38: 349–358
    1. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL, Capecitabine Colorectal Cancer Study Group (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with i.v. 5-fluorouracil (5-FU)/leucovorin. Ann Oncol 13: 566–575
    1. Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413–1418
    1. de Gramont A, Figer M, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938–2947
    1. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041–1047
    1. Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3605–3616
    1. Dunst J, Reese T, Hoelscher T, Debus J, Rudat V, Wulf J, Hinke A (2003) Preoperative radiochemotherapy with capecitabine in locally advanced rectal cancers – a phase-II-study. Eur J Cancer 1(Suppl 5): S86 (Abstract 282)
    1. FDA medical officer summary (1999) Available from: URL:
    1. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F (2000) Phase III multicenter, randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136–147
    1. Goldberg RM, Sargeant DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Alberts SR (2004) A randomised controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23–30
    1. Hartkamp A, van Boxtel AJ, Zonnenberg BA, Witteveen PO (2000) Totally implantable venous access devices: evaluation of complications and a prospective comparative study of two different port systems. Neth J Med 57: 215–223
    1. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19: 2282–2292
    1. Knight RD, Miller L, Pirotta N, Elfring G, Locker P, Saltz L (2000) First-line irinotecan (C), fluorouracil (F), leucovorin (L) especially improves survival (OS) in metastatic colorectal cancer (MCRC) patients (PT) with favorable prognostic indicators. Proc Am Soc Clin Oncol 19: 255a (Abstract 991)
    1. Köhne C-H, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schoffski P, Micheel S, Hecker H (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13: 308–317
    1. Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110–115
    1. Maindrault-Goebel F, Louvet C, André T, Carola E, Lotz JP, Molitor JL, Garcia ML, Gilles-Amar V, Izrael V, Krulik M, de Gramont A (1999) Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 35: 1338–1342
    1. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274–1281
    1. Morton RF, Goldberg RM, Sargent DJ, Fuchs CS, O'Connell MJ (2001) Oxaliplatin (OXAL) or CPT-11 combined with 5-FU/leucovorin (LV) in advanced colorectal cancer (CRC): an NCCTG/CALGB study. Proc Am Soc Clin Oncol 19: 125a (Abstract 495)
    1. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology: Colon Cancer Version 1, 2004. Available at . Accessed February 2, 2004
    1. Patt YZ, Leibmann J, Diamandidis D, Eckhardt S, Javle M, Justice GR, Keiser W, Lee F-C, Miller W, Salvatore J, Lin E (2003) Capecitabine plus irinotecan (XELIRI) in first-line metastatic colorectal cancer (MCRC): update on a phase II trial. Eur J Cancer 1(Suppl 5): S93 (Abstract 304)
    1. Ratain MJ (2002) Irinotecan dosing: does the CPT in CPT-11 stand for ‘can’t predict toxicity'? J Clin Oncol 20: 7–8
    1. Reigner B, Blesch K, Weidekamm E (2001) Capecitabine; a review of its clinical pharmacokinetics. Clin Pharmacokinet 40: 85–104
    1. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19: 3801–3807
    1. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1407–1412
    1. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905–914
    1. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H (1999) X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5: 2948–2953
    1. Schilsky R, Levin J, West WH, Wong A, Colwell B, Thirlwell MP, Ansari RH, Bell WN, White RL, Yates BB, McGuirt PV, Pazdur R (2002) Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol 20: 1519–1526
    1. Schmoll HJ (2003) Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer. Anti-cancer Drugs 14: 695–702
    1. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45: 291–297
    1. Schwarz RE, Coit DG, Groeger JS (2000) Transcutaneously tunnelled central venous lines in cancer patients: an analysis of device-related morbidity factors based on prospective data collection. Ann Surg Oncol 7: 441–449
    1. Twelves C (2001) Capecitabine (Xeloda®) vs 5-FU/LV therapy in patients with metastatic colorectal cancer (CRC): patterns of second-line therapy and potential impact on survival in randomised, phase III trials. Proc Int Congress Anticancer Treat 173(GI3-03)
    1. Twelves C (2002) Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Eur J Cancer 38(Suppl 2): S15–S20
    1. Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C, Osterwalder B, Jamieson C, Hieke K (2001) Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 37: 597–604
    1. Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, Twelves C, Allman D, Seitz JF, Scholmerich J, Burger HU, Verweij J (2000) Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 18: 1337–1345
    1. Van Cutsem E, Sorensen J, Cassidy J, Daniel F, Harper P, Bailey N, Peachey M, Somerville M (2001b) International phase III study of oral eniluracil (EU) plus 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 20: 131a (Abstract 522)
    1. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P (2001a) Oral capecitabine compared with intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097–4106
    1. Van Cutsem E, Twelves C, Tabernero J, Schoffski P, Figer A, Diaz-Rubio E, de Braud F, Conroy T, Cassidy J, Butts C (2003) XELOX: mature results of a mulitnational, phase II trial of capecitabine plus oxaliplatin, an effective first-line option for patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 22: 255 (Abstract 1023)
    1. World Health Organization (1979) World Health Organization Handbook for Reporting Results of Cancer Treatment, Publication No. 48. Geneva, Switzerland: World Health Organization

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel